These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 5398381)

  • 1. [Indications for corticotherapy in endocrine and metabolic pathology].
    Baquet R
    Maroc Med; 1969; 49(527):522-3. PubMed ID: 5398381
    [No Abstract]   [Full Text] [Related]  

  • 2. Discontinued drugs in 2008: endocrine and metabolic.
    Colca JR
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1243-55. PubMed ID: 19678796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Indications and complications of the geriatric use of corticotherapy. Clinical experience on 1028 treated cases out of 4870 aged patients hospitalized in the geriatric department].
    Ghiringhelli F; Montalbetti N; Locatelli GR; Mazzi C
    G Gerontol; 1967 Dec; 15(12):1467-76. PubMed ID: 5618943
    [No Abstract]   [Full Text] [Related]  

  • 4. Endocrine emergencies.
    Daggett P
    Br J Hosp Med; 1979 Jan; 21(1):38-44. PubMed ID: 435667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological chaperones: potential treatment for conformational diseases.
    Bernier V; Lagacé M; Bichet DG; Bouvier M
    Trends Endocrinol Metab; 2004 Jul; 15(5):222-8. PubMed ID: 15223052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [On the therapeutic use of vitamin E in clinical medicine: motivations and prospects].
    Butturini U
    Acta Vitaminol Enzymol; 1977; 31(1-5):125-42. PubMed ID: 580682
    [No Abstract]   [Full Text] [Related]  

  • 7. [Current therapeutics 1990-1995 in the field of endocrinology-metabolism].
    Scheen AJ
    Rev Med Liege; 1996 Aug; 51(8):503-9. PubMed ID: 8927870
    [No Abstract]   [Full Text] [Related]  

  • 8. Discontinued drugs in 2005: endocrine and metabolic.
    Colca JR
    Expert Opin Investig Drugs; 2007 Feb; 16(2):129-36. PubMed ID: 17243934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine emergencies. Part 1.
    Casey JH
    Med J Aust; 1980 Sep; 2(5):244-6. PubMed ID: 6776392
    [No Abstract]   [Full Text] [Related]  

  • 10. Unraveling the intricacies of receptor activated cell signaling and transcriptional cascades enhance opportunities to develop new therapeutic targets for endocrine and metabolic diseases.
    Firestone GL
    Curr Opin Pharmacol; 2010 Dec; 10(6):607-12. PubMed ID: 21036104
    [No Abstract]   [Full Text] [Related]  

  • 11. Nutrition: New diabetes nutrition recommendations--food for thought.
    Koch L
    Nat Rev Endocrinol; 2013 Dec; 9(12):687. PubMed ID: 24165995
    [No Abstract]   [Full Text] [Related]  

  • 12. [Adverse effects and complications in long term corticoid treatment in the metabolic and endocrine fields].
    Baquet R
    Maroc Med; 1969; 49(527):479-81. PubMed ID: 5398367
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society: executive summary.
    ; ; Gonzalez-Campoy JM; St Jeor ST; Castorino K; Ebrahim A; Hurley D; Jovanovic L; Mechanick JI; Petak SM; Yu YH; Harris KA; Kris-Etherton P; Kushner R; Molini-Blandford M; Nguyen QT; Plodkowski R; Sarwer DB; Thomas KT;
    Endocr Pract; 2013; 19(5):875-87. PubMed ID: 24121263
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial overview: Endocrine and metabolic diseases: Waistline weapons: new therapeutic avenues for the treatment of obesity and metabolic disease.
    Murphy KG
    Curr Opin Pharmacol; 2015 Dec; 25():iv-vi. PubMed ID: 26559147
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current antalgic anti-inflammatory drugs].
    Henrard JC
    Presse Med (1893); 1970 Jun; 78(31):1419-23. PubMed ID: 5428230
    [No Abstract]   [Full Text] [Related]  

  • 16. Differential diagnosis to rheumatoid diseases. 1. Endocrine and metabolic aspects. 2. Treatment with corticoids.
    Bassøe HH
    Scand J Rheumatol Suppl; 1984; 53():46-53. PubMed ID: 6610929
    [No Abstract]   [Full Text] [Related]  

  • 17. Discontinued drugs 2011: endocrine and metabolic.
    Colca JR
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1619-24. PubMed ID: 22917013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Indications for corticotherapy in cardiovascular pathology].
    de Vahia JL
    Maroc Med; 1969; 49(527):508-9. PubMed ID: 5398376
    [No Abstract]   [Full Text] [Related]  

  • 19. [Current therapeutic developments].
    van Cauwenberge H; Luyckx A
    Rev Med Liege; 1979 May; 34(9):413-20. PubMed ID: 472582
    [No Abstract]   [Full Text] [Related]  

  • 20. 30th International Symposium on GH and Growth Factors in Endocrinology and Metabolism. Monte Carlo, Monaco, October 6-7, 2000. Proceedings and abstracts.
    Growth Horm IGF Res; 2001 Jun; 11 Suppl A():1-160. PubMed ID: 11808495
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.